Clinical Trials Logo
  1. Home
  2. Primary Myelofibrosis (PMF)
  3. NCT04878003

Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve Myelofibrosis

Primary Myelofibrosis (PMF) Clinical Trial

Official title:
An Open-Label, Multicenter, Phase 2 Study Assessing the Safety and Efficacy of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve Myelofibrosis

Clinical Trial Summary

This study evaluates either KRT-232 or TL-895 in treatment naïve patients with myelofibrosis (MF) The study will be conducted in 2 stages. Stage 1 will evaluate safety, tolerability, and efficacy of either KRT-232 (Arm 1) or TL-895 (Arm 2) in treatment naïve patients. Stage 2 will expand enrollment in Arm 1 and/or Arm 2 if expansion criteria is met.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04878003
Study type Interventional
Source Kartos Therapeutics, Inc.
Contact John Mei
Phone 650-542-0136
Email jmei@kartosthera.com
Status Recruiting
Phase Phase 2
Start date April 13, 2021
Completion date October 2025
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03441113 - Extended Access of Momelotinib in Adults With Myelofibrosis Phase 2
Completed NCT01558739 - Exploratory Phase II Study of INC424 Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF) Phase 4
Completed NCT00910728 - Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative Diseases Phase 1
Completed NCT02101268 - Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF Phase 3
Completed NCT03136185 - Bomedemstat (IMG-7289/MK-3543) in Participants With Myelofibrosis (IMG-7289-CTP-102/MK-3543-002) Phase 1/Phase 2
Completed NCT04217993 - Jaktinib for the Treatment of Ruxolitinib Intolerance of Myelofibrosis Phase 2
Completed NCT02515630 - Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF) Phase 2
Recruiting NCT03662126 - KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment Phase 2/Phase 3
Terminated NCT03935555 - Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib Phase 1
Available NCT04745637 - Managed Access Programs for INC424, Ruxolitinib